Phase II Study (PK) of KRP-AB1102

A Multiple Dose, PhaseII Clinical Trial to Assess the Pharmacokinetics of KRP-AB1102 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221868

Enrollment

Registered

2012-07-27

Start date

2012-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

investigational material(s) Generic name etc : KRP-AB1102 INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administration for Inv

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Adult male COPD patients aged >40, and others.

Exclusion criteria

Exclusion criteria: - Current active tuberculopsis - Patient hospitalized for an acute COPD exacerbation within the previous 3 months, and others.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of KRP-AB1102 Plasma concentrations of KRP-AB1102	—

Secondary

Measure	Time frame
Safety of KRP-AB1102 Laboratory test, and others.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026